Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment
BACKGROUND: Serum hepatitis B virus RNA (HBV RNA) has been reported to be a surrogate marker of intrahepatic cccDNA during nucleos(t)ide analogs therapy. However, in HBeAg-positive patients treated with peg-interferon (peg-IFN), whether HBV RNA is superior to other HBV markers in reflecting cccDNA profile is still unclear.
METHODS: Serum HBV RNA, HBcrAg, HBV DNA, and HBsAg were longitudinally assessed among 30 HBeAg-positive patients during 48-week peg-IFN treatment. Besides, intrahepatic cccDNA was detected at baseline and week 48 respectively. Then, the individual correlations between HBV RNA, HBcrAg, HBV DNA, HBsAg, and cccDNA were statistically analyzed.
RESULTS: HBV RNA levels decreased more rapidly in patients with HBeAg seroconversion than those without HBeAg seroconversion. Among all patients, cccDNA correlated better with HBV RNA than with HBcrAg, HBV DNA, and HBsAg at baseline. After 48 weeks peg-IFN treatment, cccDNA still correlated more strongly with HBV RNA than other HBV markers. Further analysis indicated that in patients with HBeAg seroconversion cccDNA strongly correlated with HBV RNA and HBcrAg, whereas not correlate with HBV DNA and HBsAg. While in patients without HBeAg seroconversion, cccDNA highly correlated with HBV RNA and HBV DNA, moderately correlated with HBcrAg, and not correlated with HBsAg.
CONCLUSION: Compared to HBcrAg, HBV DNA, and HBsAg, serum HBV RNA correlated more strongly with intrahepatic cccDNA levels before and after 48-week peg-IFN treatment. The level of serum HBV RNA may be a superior surrogate marker in reflecting the intrahepatic cccDNA profile in HBeAg-positive patients during peg-IFN treatment. Trial registration ClinicalTrials, NCT03546530. Registered 1 January 2015. https://clinicaltrials.gov/ct2/results?cond=&term=NCT03546530.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Virology journal - 18(2021), 1 vom: 06. Jan., Seite 4 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Xiaomei [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.08.2021 Date Revised 27.08.2021 published: Electronic ClinicalTrials.gov: NCT03546530 Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12985-020-01471-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319713784 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319713784 | ||
| 003 | DE-627 | ||
| 005 | 20231225172033.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12985-020-01471-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1065.xml |
| 035 | |a (DE-627)NLM319713784 | ||
| 035 | |a (NLM)33407619 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Xiaomei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.08.2021 | ||
| 500 | |a Date Revised 27.08.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03546530 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Serum hepatitis B virus RNA (HBV RNA) has been reported to be a surrogate marker of intrahepatic cccDNA during nucleos(t)ide analogs therapy. However, in HBeAg-positive patients treated with peg-interferon (peg-IFN), whether HBV RNA is superior to other HBV markers in reflecting cccDNA profile is still unclear | ||
| 520 | |a METHODS: Serum HBV RNA, HBcrAg, HBV DNA, and HBsAg were longitudinally assessed among 30 HBeAg-positive patients during 48-week peg-IFN treatment. Besides, intrahepatic cccDNA was detected at baseline and week 48 respectively. Then, the individual correlations between HBV RNA, HBcrAg, HBV DNA, HBsAg, and cccDNA were statistically analyzed | ||
| 520 | |a RESULTS: HBV RNA levels decreased more rapidly in patients with HBeAg seroconversion than those without HBeAg seroconversion. Among all patients, cccDNA correlated better with HBV RNA than with HBcrAg, HBV DNA, and HBsAg at baseline. After 48 weeks peg-IFN treatment, cccDNA still correlated more strongly with HBV RNA than other HBV markers. Further analysis indicated that in patients with HBeAg seroconversion cccDNA strongly correlated with HBV RNA and HBcrAg, whereas not correlate with HBV DNA and HBsAg. While in patients without HBeAg seroconversion, cccDNA highly correlated with HBV RNA and HBV DNA, moderately correlated with HBcrAg, and not correlated with HBsAg | ||
| 520 | |a CONCLUSION: Compared to HBcrAg, HBV DNA, and HBsAg, serum HBV RNA correlated more strongly with intrahepatic cccDNA levels before and after 48-week peg-IFN treatment. The level of serum HBV RNA may be a superior surrogate marker in reflecting the intrahepatic cccDNA profile in HBeAg-positive patients during peg-IFN treatment. Trial registration ClinicalTrials, NCT03546530. Registered 1 January 2015. https://clinicaltrials.gov/ct2/results?cond=&term=NCT03546530 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a HBV DNA | |
| 650 | 4 | |a HBV RNA | |
| 650 | 4 | |a HBcrAg | |
| 650 | 4 | |a Hepatitis B virus | |
| 650 | 4 | |a Interferon | |
| 650 | 4 | |a cccDNA | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a DNA, Circular |2 NLM | |
| 650 | 7 | |a DNA, Viral |2 NLM | |
| 650 | 7 | |a Hepatitis B Core Antigens |2 NLM | |
| 650 | 7 | |a Hepatitis B Surface Antigens |2 NLM | |
| 650 | 7 | |a Hepatitis B e Antigens |2 NLM | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 650 | 7 | |a Interferons |2 NLM | |
| 650 | 7 | |a 9008-11-1 |2 NLM | |
| 700 | 1 | |a Chi, Xiumei |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Ruihong |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Hongqin |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Xiuzhu |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Longgen |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Mingxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Youwen |e verfasserin |4 aut | |
| 700 | 1 | |a Niu, Junqi |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Qinglong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Virology journal |d 2004 |g 18(2021), 1 vom: 06. Jan., Seite 4 |w (DE-627)NLM151772509 |x 1743-422X |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2021 |g number:1 |g day:06 |g month:01 |g pages:4 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12985-020-01471-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2021 |e 1 |b 06 |c 01 |h 4 | ||